Ziconotide

Overview

Plain-language guide

Clinical mechanism

Blocks N-type voltage-sensitive calcium channels in the spinal cord.

Applications

• Severe chronic pain

Human evidence

Multiple human studies and regulatory review support at least one product-specific indication.

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

Regulatory status

Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

Safety

Known but Manageable Risks

• Adverse effects vary by product and indication
• Contraindications and interactions require label review

Interactions

Review the current product label and indication-specific literature for pharmacologic and absorption interactions.

Treatment pattern

Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.

Manufacturing and quality

Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.

Sponsor and development history

TerSera Therapeutics · Approved. Development programs and ownership can change; confirm current sponsor disclosures.

Sources

1. 01
   Primary regulatory record

   Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

2. 02
   Clinical trial registry

   Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

3. 03
   Peer-reviewed literature

   Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

Gaps and unverified claims

• Evidence must be interpreted by indication and product label.
• Approval does not establish safety or efficacy for off-label or compounded copies.

Last reviewed

August 5, 2026 · Draft